Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The fight against lung cancer has entered a new era, largely driven by breakthroughs in targeted therapies and our growing understanding of cancer's genetic underpinnings. For specific subsets of lung cancer, such as ALK-positive non-small cell lung cancer (NSCLC), personalized medicine approaches have revolutionized treatment paradigms, offering more effective and less toxic options than traditional chemotherapy.
Lorlatinib, a third-generation ALK inhibitor, exemplifies the progress made in this field. Its development was a direct response to the limitations of earlier treatments, particularly the emergence of resistance mutations and the significant challenge posed by brain metastases. By targeting these specific molecular drivers, lorlatinib provides a more durable response and improved efficacy, especially in patients with advanced disease. The continued research into these targeted agents is critical for further optimizing patient outcomes.
Looking ahead, the future of lung cancer treatment will likely involve even more sophisticated targeted therapies, potentially combined with immunotherapies or novel drug delivery systems. The ongoing exploration of biomarkers, alongside advancements in drug discovery and development, is paving the way for highly individualized treatment strategies. Pharmaceutical companies and research institutions are continuously working to identify new targets and develop novel compounds that can overcome resistance and manage even the most challenging forms of lung cancer.
The consistent supply of high-quality pharmaceutical intermediates and active ingredients, such as those provided by NINGBO INNO PHARMCHEM CO.,LTD., is fundamental to this progress. By ensuring the availability of essential components for drug manufacturing, these companies play a crucial role in making these life-changing therapies accessible to patients worldwide. The continued investment in research and development, coupled with reliable pharmaceutical supply chains, promises a brighter future for individuals diagnosed with lung cancer.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
